Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations
Executive Summary
Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line
You may also be interested in...
Medco/Merck Contract Gets New Spin; Renegotiation May Avert Zocor Impact
Medco's renegotiation of its rebate agreement with Merck may have allowed the pharmacy benefit manager to avoid loss of rebates accompanying Zocor'slooming patent expiration
Medco/Merck Contract Gets New Spin; Renegotiation May Avert Zocor Impact
Medco's renegotiation of its rebate agreement with Merck may have allowed the pharmacy benefit manager to avoid loss of rebates accompanying Zocor'slooming patent expiration
Medco Suits Complicate Merck Spin-Off Plans, Position In Medicare Debate
The unsealing of two "whistleblower" complaints filed against Medco Health Solutions is the latest complication in Merck's plans to spin-off the pharmacy benefit management division